Supriya Lifescience Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Strong return on equity (ROE 19.1%)
- Attractively valued vs sector (P/E 35.3x vs industry 50.2x)
- Virtually debt-free
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SUPRIYA · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% |
| FII | 4.56% | 5.37% | 4.95% | 6.03% | 6.52% | 7.19% |
| DII | 5.39% | 5.30% | 5.48% | 5.45% | 4.93% | 4.26% |
| Public | 21.77% | 21.04% | 21.27% | 20.22% | 20.25% | 20.25% |
Corporate Events
Dividend - Re 1 Per Share
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Re 1 Per Share
Record: 4 Sept 2025
Annual General Meeting/Dividend - Rs 0.80 Per Share
Annual General Meeting/Dividend - Re 0.60 Per Share
Latest News
All newsSupriya Lifescience issues general corporate updates
*Supriya Lifescience issues general corporate updates.* The company filed routine disclosures with the NSE, containing no major financial or operational announcements. Such updates typically include administrative or compliance-related information. No significant business developments were reported. 📊 *STOCKS:* $SUPRIYA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
Supriya Lifescience receives ESG rating from CRISIL
*Supriya Lifescience receives ESG rating from CRISIL*. CRISIL has assigned an ESG rating to Supriya Lifescience Limited, reflecting its environmental, social, and governance performance. The rating may influence investor sentiment over the long term. No financial figures or immediate business changes were disclosed. 📊 *STOCKS:* $SUPRIYA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG
Supriya Lifescience announces general corporate updates
*Supriya Lifescience announces general corporate updates.* The filing provides routine disclosures with no major financial or operational changes. **No significant figures** or strategic shifts were revealed. Investors are advised to monitor for further announcements. 📊 *STOCKS:* $SUPRIYA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
Supriya Lifescience to host analyst investor meet
*Supriya Lifescience to host an analyst and institutional investor meet.* The event aims to provide updates on company performance and strategy. **No financial figures or major announcements** were disclosed in the filing. This is a routine engagement for market transparency. 📊 *STOCKS:* SUPLIFE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings